Mumbai: HCG Manavata Cancer Centre has successfully performed its first PIPAC (Pressurised IntraPeritoneal Aerosol-Chemotherapy) procedure—a highly advanced, minimally invasive technique used in managing advanced abdominal cancers. This pioneering technique was performed on a patient diagnosed with advanced-stage stomach cancer.
The surgery was conducted under the expert guidance of Dr. Ninad Katdare from HCG Cancer Centre, Mumbai, in collaboration with Dr. Raj Nagarkar, Managing Director and Chief of Surgical Oncology and Robotic Services at HCG Manavata Cancer Centre.
PIPAC is widely adopted in international oncology centers for treating peritoneal cancers unacceptable through conventional surgical or chemotherapy means. It includes cancers originating in the stomach, ovaries, and colon.
Prof. Dr. Raj Nagarkar, Chief of Surgical Oncology and Robotic Services at KIMS Manavata Hospitals, HCG Manavata Cancer Centre, said, “The breakthrough technique allows chemotherapy to be delivered directly into the peritoneal cavity in an aerosolized form using laparoscopic access. The pressurized delivery improves drug penetration, providing targeted treatment that avoids harmful systemic effects. It not only maximizes the therapeutic value but also enhances patient comfort and recovery.” He highlighted the pivotal advantages of PIPAC, including local, high-concentration drug delivery directly into the peritoneal cavity, which enhances therapeutic impact on cancerous tissues. It also minimizes toxicity to healthy organs, reducing systemic side effects, and patients benefit from faster recovery due to the minimally invasive nature of the procedure.
